Endra Life Sciences Inc Stock Price, News & Analysis

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has been granted its 13th U.S. patent, number 10888898, for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers enhanced imaging capabilities for diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This patent solidifies intellectual property protection in a market where NAFLD affects 30% of the U.S. population. ENDRA's commercial launch plans include establishing international research partnerships, with recent installations in major hospitals. The company continues to expand its patent portfolio, now totaling 78 assets.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. Chairman and CEO Francois Michelon will showcase the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which visualizes tissue at a fraction of the cost of MRI, aimed initially at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). The presentation will be available on the company's website starting January 11 at 6:00 a.m. Eastern time and archived for 90 days.

ENDRA Life Sciences (NASDAQ:NDRA) has been granted Chinese Patent ZL 2018 8 00500526 for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology. This patent, the eighth for ENDRA in China, enhances its intellectual property portfolio, now totaling 78 assets. TAEUS provides a non-invasive method to assess liver fat, crucial for the estimated 30% of China's population suffering from Non-Alcoholic Fatty Liver Disease (NAFLD). The technology offers a cost-effective alternative to MRIs and biopsies, utilizing existing ultrasound systems for patient care.

ENDRA Life Sciences (NASDAQ: NDRA) has renewed its collaboration agreement with GE Healthcare, extending the partnership until December 16, 2023. This agreement will support the commercialization of ENDRA's TAEUS technology for imaging Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Recent advancements include deployment of TAEUS systems at Rocky Vista University and UPMC, a clinical evaluation agreement in France, and an exclusive distribution deal in Vietnam for over 40 systems. ENDRA aims to enhance ultrasound capabilities and address critical clinical needs in liver assessments.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has completed its public offering of 7,857,286 shares of common stock at $0.70 per share, raising $5,500,100 before expenses. The underwriter, ThinkEquity, exercised its over-allotment option for an additional 714,286 shares. The offering was made under an effective shelf registration statement filed with the SEC. ENDRA focuses on developing its TAEUS technology for improved tissue visualization, particularly for liver conditions affecting over 1 billion people globally, which currently lack practical diagnostic tools.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a public offering of 7,143,000 shares of common stock priced at $0.70 per share, aiming to raise approximately $5.0 million before expenses. The underwriter has a 45-day option to purchase an additional 714,286 shares to cover over-allotments, potentially increasing gross proceeds to $5.5 million. The offering is slated to close on December 18, 2020. Funds will be allocated for working capital and general corporate purposes.

ENDRA Life Sciences (NASDAQ:NDRA) announced a proposed underwritten public offering of common stock. The company plans to grant the underwriter a 45-day option to purchase additional shares. The offering is subject to market conditions, with no guarantee on its completion or terms. ENDRA intends to utilize the net proceeds for working capital and general corporate purposes. ThinkEquity is acting as the sole underwriter. A shelf registration statement has been filed with the SEC, and preliminary prospectus materials will also be available.

ENDRA Life Sciences (NASDAQ:NDRA) has received its seventh Chinese patent for TAEUS technology, aimed at addressing clinical needs like Non-Alcoholic Fatty Liver Disease. The new patent, ZL 2016 8 00267062, enhances ENDRA’s intellectual property protection in China, where approximately 30% of the population is affected by liver disease. The company’s patent portfolio now includes 78 assets, with further developments expected in the US and Europe. This patent supports ENDRA’s goal of optimizing hybrid ultrasound and thermoacoustic imaging for various clinical applications.

ENDRA Life Sciences (NASDAQ: NDRA) has signed an exclusive distribution agreement with Quang Phat Technology Science Equipment Co. Ltd. to sell at least 40 TAEUS liver imaging systems in Vietnam. The agreement, effective over three years, hinges on securing FDA clearance and local approvals before sales commence. This marks ENDRA's first commercial agreement in Southeast Asia, aimed at addressing the rising incidence of NAFLD in Vietnam's 96 million population. ENDRA aims to capitalize on its innovative technology to provide non-invasive liver disease diagnostics.